This week's roundup of Houston innovators includes Jim Gable of Chevon, Brad Burke of Rice Alliance, and Chris Romani of illumipure. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from academia to energy tech — recently making headlines in Houston innovation.

Houston energy innovator on why now's the right time for energy transition innovation

Jim Gable, vice president of innovation at Chevron and president of Chevron Technology Ventures, joins the Houston Innovators Podcast. Photo courtesy

The cleantech innovation space has momentum, and Chevron strives to be one of the incumbent energy companies playing a role in that movement, Jim Gable, vice president of innovation at Chevron and president of Chevron Technology Ventures, shares on the Houston Innovators Podcast.

"People call it cleantech 2.0, but it's really cleantech 3.0," Gable says, explaining how he's been there for each wave of cleantech. "The people are better now — the entrepreneurs are better, the investors are better. Exits are here in the cleantech space."

"It's all driven by policy-enabled markets, and the policy is here now too. Twenty years ago, you didn't have nearly the same level of policy influence that you do now," he continues. "Things are coming together to help us really create and deliver that affordable, reliable, ever cleaner energy that's going to be needed for a long time." Read more.

Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship

Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship, has received an impressive award for his leadership. Photo via Rice.edu

A figurehead in Houston's innovation ecosystem has received an award for his career leading innovation in higher education.

Brad Burke, who's served as managing director of the Rice Alliance for Technology and Entrepreneurship since its inception 22 years ago, received the Outstanding Contributions to Advancing Innovation and Entrepreneurship in Higher Education Award. Burke was presented with the award at the 2023 Deshpande Symposium for Innovation and Entrepreneurship in Higher Education.

Recognizing an individual who has proven to be successful in leading entrepreneurship within higher education, the award was founded by serial entrepreneur Desh Deshpande. The event attracts academics, policy planners, and practitioners every year to share thought leadership within higher education entrepreneurship and innovation. Read more.

Chris Romani, chief marketing officer for illumiPure

If mobile marketing isn't in your startup's toolkit, it should be. Photo courtesy

When it comes to marketing tools, there's a lot out there. Some aren't worth it, but some can make a huge difference. Chris Romani, chief marketing officer for illumiPure, Houston-based medical device company, in a guest column for InnovationMap, outlined some of the tools that make an impact.

"For startups, when and how to begin marketing their business can feel like a cumbersome task," he explains. "As a chief marketing officer, I was asked to list services and channels that I oversee, and I came up with 16. For founders of startups who must often take on the roles of CEO and COO in addition to CMO as they look to expand their teams, that time commitment is not reasonable for someone who also has a personal life." Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.